Glyconutrient - Glyconutrients or Glyconutritionals

Glyconutrient Monosaccharides - are a special class of carbohydrates that your body uses to create glycoproteins, compounds which are essential for proper cell-to-cell communication. Visit the website, on Glyconutrients information for the current information on Glyconutrients. Cell-to-cell communication is a process that is integral to every aspect of your health. -

Companies Look to Plug the Asbestos Drain
Proponents of a bill to rein in asbestos lawsuits say this could be the year legislation is finally approved on Capitol Hill. Court cases have cost companies billions of dollars, while also helping to push dozens of firms into bankruptcy. But given the mounting debate over the proposed legislation, ...

Alimta treatment for malignant pleural mesothelioma
The company's Alimta treatment for malignant pleural mesothelioma saw sales of $73.1 million, up from $40 million in the third quarter, while sales of depression treatment Cymbalta were $61.3 million, compared with $32.5 million in the third quarter, mainly due to initial wholesaler stocking. Fourth-quarter sales of Forteo, a treatment ...

Bush makes litigation reform stop in Macomb.
President George W. Bush made his first stop in Michigan since his re-election, and the main topic of his agenda was asbestos litigation reform. Bush spoke to an invitation-only crowd at the Macomb Center for the Performing Arts Jan. 7. He was joined by four other guests, one being an ...

Allos Therapeutics, Inc. (ALTH) Initiates Phase 1 PDX Study
Allos Therapeutics, Inc. today announced the initiation of a Phase 1 dose escalation study of its investigational drug PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with previously-treated (Stage IIIB-IV) advanced non-small cell lung cancer (NSCLC). This open-label, non-randomized study will seek to enroll one to six ...

Malignant Pleural Mesothelioma European Prognosis Score Validated
European Prognosis Score Validated in Malignant Pleural Mesothelioma: A recent article in the Journal of Clinical Oncology reports that the current model for determining the prognosis for malignant pleural mesothelioma (MPM) is a valid tool for determining high and low-risk patients for clinical trial participation. The current model for determining the ...